Prevalence of Colorectal Neoplasms Among Patients With Enterococcus faecalis Endocarditis in the GAMES Cohort (2008-2017)
Por:
Pericas, JM, Ambrosioni, J, Munoz, P, de Alarcon, A, Kestler, M, Mari-Hualde, A, Moreno, A, Goenaga, MA, Farinas, MC, Rodriguez-Alvarez, R, Ojeda-Burgos, G, Galvez-Acebal, J, Hidalgo-Tenorio, C, Noureddine, M, Miro, JM, Benito N., Gurgui M., GAMES Investigators
Publicada:
1 ene 2021
Ahead of Print:
1 ene 2021
Resumen:
Objective: To investigate the rate of colorectal neoplasms (CRNs) in patients who have Enterococcus faecalis infective endocarditis (EFIE) with available colonoscopies and to assess whether this is associated with the identification of a focus the infection.
Patients and Methods: Retrospective analysis of data from a prospective multicenter study involving 35 centers who are members of the Grupo de Apoyo para el Manej o de la Endocarditis en Espana [Support Group for the Management of Infective Endocarditis in Spain] cohort. A specific set of queries regarding information on colonoscopy and histopathology of colorectal diseases was sent to each participating center. Four-hundred sixty-seven patients with EFIE were included from January 1, 2008, to December 31, 2017, from whom data on colonoscopy performance and results were available in 411 patients.
Results: One hundred forty-two (34.5%) patients had a colonoscopy close to the EFIE episode. The overall rate of colorectal diseases was 70.4% (100 of 142), whereas the prevalence of CRN (advanced adenomas and colorectal carcinoma) was 14.8% (21 of 142), with no significant differences between the group of EFIE of unknown focus and that with an identified focus.
Conclusion: Our study adds to prior evidence suggesting a much higher rate of CRN among patients with EFIE than in the general population of the same age and sex. In addition, our findings suggest that this phenomenon might take place both in EFIE with an unknown and an identified source of infection. (C) 2020 Mayo Foundation for Medical Education and Research
Filiaciones:
Pericas, JM:
Univ Barcelona, Hosp Clin Barcelona, IDIBAPS, Barcelona, Spain
Vall dHebron Inst Res VHIR, Vall dHebron Barcelona Hosp Campus, Barcelona, Spain
Ambrosioni, J:
Univ Barcelona, Hosp Clin Barcelona, IDIBAPS, Barcelona, Spain
Munoz, P:
Univ Complutense Madrid, Hosp Gen Univ Gregorio Maranon, Madrid, Spain
CIBERES CB06 06 0058, Inst Invest Biomed Gregorio Maranon, Madrid, Spain
de Alarcon, A:
Hosp Univ Virgen del Rocio, Seville, Spain
Kestler, M:
Univ Complutense Madrid, Hosp Gen Univ Gregorio Maranon, Madrid, Spain
Mari-Hualde, A:
Univ Complutense Madrid, Hosp Gen Univ Gregorio Maranon, Madrid, Spain
Moreno, A:
Univ Barcelona, Hosp Clin Barcelona, IDIBAPS, Barcelona, Spain
Goenaga, MA:
Hosp Univ Donostia, Donostia San Sebastian, Spain
Farinas, MC:
Hosp Univ Marques de Valdecilla, Santander, Spain
Rodriguez-Alvarez, R:
Hosp Univ Cruces, Baracaldo, Spain
Ojeda-Burgos, G:
Hosp Univ Virgen de la Victoria, Malaga, Spain
Galvez-Acebal, J:
Univ Seville, Hosp Univ Virgen de la Macarena, Seville, Spain
Hidalgo-Tenorio, C:
Hosp Univ Virgen de las Nieves, Granada, Spain
Noureddine, M:
Hosp Costa del Sol, Marbella, Spain
Miro, JM:
Univ Barcelona, Hosp Clin Barcelona, IDIBAPS, Barcelona, Spain
Benito N.:
Institut d’Investigació Biomèdica Sant Pau (IIB SANT PAU), Sant Quintí 77-79, 08041 Barcelona, Spain
Gurgui M.:
Institut d’Investigació Biomèdica Sant Pau (IIB SANT PAU), Sant Quintí 77-79, 08041 Barcelona, Spain
Bronze
|